Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
07
02
2024
accepted:
24
04
2024
revised:
22
04
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
Total body irradiation (TBI)-based conditioning regimens are generally recommended for allogeneic HSCT (allo-HSCT) in patients with acute lymphoblastic leukemia (ALL). Recent evidence suggests that modern chemotherapy-based regimens may be as effective. This multicenter retrospective study compared the clinical outcomes of myeloablative allo-HSCT with thiotepa, busulfan, and cyclophosphamide/fludarabine (TTB) to TBI-based conditioning. Between 2002 to 2018, 63 and 114 patients received TTB- and TBI-based conditioning regimens, respectively. The 5-year cumulative incidence of relapse was lower in the TBI cohort compared to the TTB cohort (30% [95% CI, 22-38] versus 47% [95% CI, 36-59]; P = 0.03). Multivariate analysis identified T-ALL, Ph-negative B-ALL, and measurable residual disease associated with a higher relapse risk. The 5-year cumulative incidence of non-relapsed mortality (NRM) was significantly lower with TTB (12% [95% CI, 5-20]) compared to TBI (25% [95% CI, 18-33]) (P = 0.001). Multivariate analysis found TBI conditioning, older age, and advanced stages of ALL at transplantation associated with a higher NRM. No statistical difference was seen in overall survival (49% [95% CI, 40-58] and 46% [95% CI, 35-60]) in the TBI and TTB groups, respectively; P = 0.9). The study suggests that TTB-based conditioning may be a promising option for ALL patients undergoing allo-HSCT, as it resulted in similar OS and lower NRM than TBI-based conditioning.
Identifiants
pubmed: 38755458
doi: 10.1038/s41409-024-02298-z
pii: 10.1038/s41409-024-02298-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54:798–809.
doi: 10.1038/s41409-018-0373-4
pubmed: 30385870
DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, DeAngelo DJ, Kebriaei P, et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2113–23.
doi: 10.1016/j.bbmt.2019.08.014
pubmed: 31446198
Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, et al. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transpl. 2016;22:2194–200.
doi: 10.1016/j.bbmt.2016.09.007
Eroglu C, Pala C, Kaynar L, Yaray K, Aksozen MT, Bankir M, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54:2474–9.
doi: 10.3109/10428194.2013.779691
pubmed: 23442062
Kebriaei P, Anasetti C, Zhang M-J, Wang H-L, Aldoss I, de Lima M, et al. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018;24:726–33.
DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017;123:3073–9.
doi: 10.1002/cncr.30695
pubmed: 28369839
Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D, et al. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study. Biol Blood Marrow Transpl. 2015;21:1932–8.
doi: 10.1016/j.bbmt.2015.06.011
Chen Y-B, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121:226–33.
doi: 10.1002/cncr.29023
pubmed: 25204639
Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A, et al. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the Euro. Eur J Haematol. 2015;96:90–7.
doi: 10.1111/ejh.12553
pubmed: 25807864
Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, et al. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:18–22.
doi: 10.1002/ajh.24567
pubmed: 27673280
Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, et al. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:997–1003.
doi: 10.1002/ajh.24823
pubmed: 28614903
Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transpl. 2013;48:630–41.
doi: 10.1038/bmt.2012.139
Shen Z, Gu X, Mao W, Yin L, Yang L, Zhang Z, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18:755.
doi: 10.1186/s12885-018-4670-5
pubmed: 30037340
pmcid: 6056932
Pavlů J, Labopin M, Niittyvuopio R, Socie G, Yakoub-Agha I, Wu D, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108.
doi: 10.1186/s13045-019-0790-x
pubmed: 31647022
pmcid: 6813121
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
doi: 10.1097/00007890-197410000-00001
pubmed: 4153799
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.
doi: 10.1016/0002-9343(80)90380-0
pubmed: 6996481
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
pubmed: 10204198
Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496–509.
doi: 10.1080/01621459.1999.10474144
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.
pubmed: 5910392
Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B. 1972;34:187–220.
doi: 10.1111/j.2517-6161.1972.tb00899.x
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; R Core Team: 2020. Available from: https://www.R-project.org/ .
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.
doi: 10.1016/S1470-2045(10)70127-3
pubmed: 20558104
pmcid: 3163510
Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, et al. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol. 2017;92:171–8.
doi: 10.1002/ajh.24613
pubmed: 27880980
Uncu UB, Yiğenoğlu TN, Şahin D, Başcı S, İskender D, Adaş Y, et al. Does Total Body Irradiation Have a Favorable Impact on Thrombocyte Engraftment as per Neutrophil Engraftment in Allogeneic Stem Cell Transplantation? Cureus Cureus. 2021;13:e19462.
Boström L, Ringdén O, Jacobsen N, Zwaan F, Nilsson B. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors-acute graft-versus-host disease, and splenectomy. Transplantation. 1990;49:1100–5.
doi: 10.1097/00007890-199006000-00014
pubmed: 2193443
Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR, et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transpl. 1994;13:455–60.
Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transpl. 1998;22:755–61.
doi: 10.1038/sj.bmt.1701423
Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transpl. 2001;27:727–30.
doi: 10.1038/sj.bmt.1702868
Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–51.
doi: 10.1182/blood.V98.7.2043
pubmed: 11567988
D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transpl. 2020;26:e177–82.
doi: 10.1016/j.bbmt.2020.04.013
Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia. Cancer. 2006;106:2657–63.
doi: 10.1002/cncr.21932
pubmed: 16703597
Ribera J-M, Oriol A, González M, Vidriales B, Brunet S, Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87–95.
doi: 10.3324/haematol.2009.011221
pubmed: 19797728
Brissot E, Labopin M, Beckers MM, Socie G, Rambaldi A, Volin L, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100:392–9.
doi: 10.3324/haematol.2014.116954
pubmed: 25527562
pmcid: 4349279
Park H, Byun JM, Koh Y, Yoon S-S, Park H, Lee J, et al. Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation-Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study. Clin Lymphoma Myeloma Leuk. 2019;19:1–11.
doi: 10.1016/j.clml.2019.08.005
Peters C, Dalles J-H, Locatelli F, Poetschger U, Pichler H, Sedlacek P, et al. TBI or chemotherapy based conditioning for children and adolescents with ALL: A prospective randomized multicenter-study “FORUM” on behalf of the AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG and EBMT-PD-WP. Haematologica. 2020;105:S102.
Montoro J, Piñana JL, Hernández-Boluda JC, Hernani R, Lorenzo I, Pérez A, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplant. 2020;14:641–13.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157–68.